Discussion stirs around Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) this week; here is what analysts are saying.

October 2, 2018 - By Peter Erickson

Investors sentiment increased to 2.09 in Q2 2018. Its up 0.91, from 1.18 in 2018Q1. It improved, as 14 investors sold Spectrum Pharmaceuticals, Inc. shares while 30 reduced holdings. 30 funds opened positions while 62 raised stakes. 90.61 million shares or 14.22% more from 79.34 million shares in 2018Q1 were reported.
Gp One Trading Ltd Partnership holds 10,624 shares or 0% of its portfolio. Moreover, Chicago Equity Ptnrs Ltd Liability Company has 0.02% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Piedmont Advsr Ltd Liability Company reported 0.02% stake. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 6,083 shares. 16.53 million are owned by Blackrock. The Michigan-based Ls Investment Advisors Limited Liability Company has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Amalgamated Bancshares holds 0.01% or 15,785 shares in its portfolio. 135,095 are owned by Guggenheim Ltd Liability. Commonwealth Of Pennsylvania School Empls Retrmt System owns 0.01% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 19,810 shares. 113,548 are held by Barclays Public Limited Liability Com. Price T Rowe Associates Md has invested 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). State Of Wisconsin Invest Board, Wisconsin-based fund reported 100,900 shares. 18,771 were reported by Walleye Trading Ltd Co. Halcyon Mngmt Partners Lp reported 159,842 shares. Sio Capital Mgmt Ltd Com has invested 1.66% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).

Since April 2, 2018, it had 0 insider buys, and 15 insider sales for $14.41 million activity. Turgeon Joseph W. sold $219,751 worth of stock or 11,565 shares. $1.36M worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares were sold by SHROTRIYA RAJESH C MD. On Thursday, May 17 the insider Krassner Stuart Mitchell sold $399,880. The insider COHEN RAYMOND W sold $169,918.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

Among 2 analysts covering Spectrum Pharmaceuticals (NASDAQ:SPPI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharmaceuticals had 5 analyst reports since April 10, 2018 according to SRatingsIntel. FBR Capital maintained the shares of SPPI in report on Tuesday, April 10 with “Buy” rating. FBR Capital maintained it with “Buy” rating and $2600 target in Tuesday, June 26 report. The firm earned “Buy” rating on Monday, May 14 by FBR Capital. The firm earned “Buy” rating on Friday, August 31 by FBR Capital. The rating was maintained by H.C. Wainwright on Friday, May 4 with “Buy”. Below is a list of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) latest ratings and price target changes.

31/08/2018 Broker: FBR Capital Old Rating: Buy New Rating: Buy Old Target: $26 New Target: $35 Maintain
26/06/2018 Broker: FBR Capital Rating: Buy New Target: $26.0000 Maintain
14/05/2018 Broker: FBR Capital Rating: Buy New Target: $26.0000 Maintain
04/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $33.0000 Maintain
10/04/2018 Broker: FBR Capital Rating: Buy New Target: $26.0000 Maintain

The stock decreased 1.80% or $0.305 during the last trading session, reaching $16.615. About 532,436 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has risen 96.95% since October 2, 2017 and is uptrending. It has outperformed by 81.33% the S&P500.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $1.74 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.